6:38 AM
 | 
Jun 26, 2018
 |  BC Extra  |  Company News

No right-to-try for BrainStorm's ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) will not make its NurOwn therapy available under the U.S. right-to-try law, it announced Tuesday.

NurOwn is in a Phase III trial to treat amyotrophic lateral sclerosis. It consists of autologous mesenchymal stromal cells induced to differentiate into neurotrophic factor-secreting cells.

BrainStorm said it...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >